Keywords: Pfizer, Inlyta, Bosutinib, USA, FDA, Kidney cancer, Myeloid leukemia

FDA OKs Pfizer’s Inlyta and accepts NDA for bosutinib

Article | 30 January 2012

Print This

The US Food and Drug Administration on Friday approved global pharma behemoth Pfizer’s (NYSE: PFE) Inlyta (axitinib) to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in